Lenabasum

Lenabasum
Clinical data
Trade names	Lenabasum
Routes of; administration	Oral
ATC code	None;
Legal status
Legal status	Investigational;
Pharmacokinetic data
Metabolism	Minimal
Identifiers
	IUPAC name (6aR,10aR)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid;
JSmol)	Interactive image;
	SMILES OC(C1=CC[C@](C(C)(C)OC2=C3C(O)=CC(C(C)(C)CCCCCC)=C2)([H])[C@@]3([H])C1)=O;
	InChI InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10-11,14-16,18-19,26H,6-9,12-13H2,1-5H3,(H,27,28)/t16?,18-,19-/m1/s1 ; Key:QHGPTMABBHVVQU-VOBHOPKGSA-N ;
	(what is this?) (verify)

Lenabasum (also known as ajulemic acid, 1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid, DMH-D8-THC-11-OIC, AB-III-56, HU-239, IP-751, CPL 7075, CT-3, JBT-101, Anabasum, and Resunab) is a

lipoxin A4 and prostaglandin J2. Studies in animals at doses up to 40 mg/kg show minimal psychoactivity of lenabasum, compared to that produced by tetrahydrocannabinol.^[6] Lenabasum is being developed by Corbus Pharmaceuticals (formerly JB Therapeutics) for the treatment of orphan chronic life-threatening inflammatory diseases.^[7] Development since been discontinued.^[8]

References

PMID 15240185
.

S2CID 15593252
.

PMID 29238967
.

S2CID 582590
.

PMID 16146336
.

PMID 17105826
.

^ "Companies To Watch: Corbus Pharmaceuticals". www.lifescienceleader.com. Retrieved 2019-05-20.

^ "Lenabasum". AdisInsight.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lenabasum&oldid=1212986460"

[pmid15240185-1] PMID 15240185
.

[2] S2CID 15593252
.

[3] PMID 29238967
.

[pmid15925096-4] S2CID 582590
.

[pmid16146336-5] PMID 16146336
.

[6] PMID 17105826
.

[7] "Companies To Watch: Corbus Pharmaceuticals". www.lifescienceleader.com. Retrieved 2019-05-20.

[8] "Lenabasum". AdisInsight.

[6]

[7]

[8]